Separately, in a small cohort of CLL patients evaluated after HCT, CD8+ responses to neoantigens created from patient-specific non-Ig somatic mutations were identified; one well-studied patient-derived T cell clone could lyse autologous primary CLL cells, indicating that the epitope the clone recognized was a true personal neoantigen (13). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.